Nucleic acid molecule, expression vector and microorganism for preparing human milk oligosaccharide

By screening and optimizing α-1,2-fucosyltransferase BKHT, an efficient expression vector and microorganism were constructed, which solved the problems of insufficient catalytic vitality and substrate specificity in the prior art, and achieved efficient and without by-products 2'-fucosyl lactose production reduces production costs.

CN116042671BActive Publication Date: 2024-11-22BLOOMAGE BIOTECHNOLOGY CORP LTD +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310120743.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-14
Publication Date
2024-11-22
Estimated Expiration
2043-02-14

AI Technical Summary

Technical Problem

In the existing 2'-fucosyl lactose production methods, ɑ-1,2-fucosyl transferase has low catalytic activity and poor substrate specificity, resulting in the generation of by-product difucosyl tetrasaccharides, which increases The downstream separation and purification cost and the conversion rate of lactose to 2'-FL are improved, and the material input cost is increased.

Method used

The α-1,2-fucosyltransferase BKHT protein was screened and optimized, and its expression vector and microorganisms containing the BKHT-encoding gene were constructed. The synthesis of 2'-fucosyl lactose through the efficient catalytic enzyme was performed to reduce the generation of by-products.

Benefits of technology

The high yield and high conversion rate of 2'-fucosyl lactose were achieved, with the yield reaching 94.68g/L and the lactose conversion rate reaching 0.98mol 2'-FL/mol lactose, which significantly reduced the downstream isolation and purification cost and had good Industrialization prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116042671B_ABST
    Figure CN116042671B_ABST
Patent Text Reader

Abstract

The present invention provides a nucleic acid molecule encoding a BKHT protein, the nucleic acid molecule comprising a sequence as shown in SEQ ID NO.2 or a nucleotide sequence having at least 98% sequence identity with SEQ ID NO.2. The BKHT protein encoded by the nucleic acid molecule is derived from Helicobacter pylori sp.13S00401-1, and its amino acid sequence is shown in SEQ ID NO.1. The protein has excellent α-1,2-fucosyltransferase catalytic activity and strict substrate specificity. When the protein is used to catalyze GDP-fucose and lactose to synthesize 2'-fucosyllactose, the yield of 2'-fucosyllactose can reach 94.68 g / L, and the lactose conversion rate can reach 0.98 mol 2'-FL / mol lactose, especially the generation of by-product difucosyllactose, which has good industrialization prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of bioengineering technology, and in particular to a nucleic acid molecule, an expression vector and a microorganism for preparing human milk oligosaccharides. Background Art

[0002] Human milk oligosaccharides (HMOs) are the third largest solid substance in breast milk after lactose and fat, and are an indispensable component for infant development. Among the more than 200 identified HMOs, 2'-fucosyllactose (2'-FL) is the oligosaccharide with the highest content among HMOs. It is also one of the first HMOs approved by the US FDA and the EU to be added to infant formula, regular foods, dietary supplements and / or medical foods, and has received widespread attention. However, the current production cost of 2'-FL is high and the production method has certain limitations.

[0003] Currently, the production methods of 2'-fucosyllactose mainly include chemical synthesis, enzyme catalysis and microbial fermentation. Chemical synthesis requires high cost of raw materials, and requires the introduction of protective groups, which is cumbersome. In contrast, enzyme catalysis and biological fermentation have mild reaction conditions and are green, making them the most competitive production methods.

[0004] The key to producing 2'-fucosyllactose by enzyme catalysis or biofermentation is to screen for ɑ-1,2-fucosyltransferases with high activity and high substrate specificity. At present, the ɑ-1,2-fucosyltransferases publicly used for the synthesis of 2'-FL are mainly FucT2 from Helicobacter pylori and WbgL from Escherichia coli O126, but these two enzymes still have problems such as low catalytic activity and poor substrate specificity. The synthesis of 2'-FL is accompanied by the synthesis of the byproduct difucosylate DFL, which greatly increases the cost of downstream separation and purification, and also reduces the conversion rate of lactose to 2'-FL, which also increases the material input cost invisibly. Summary of the invention

[0005] The purpose of the present invention is to provide a nucleic acid molecule, an expression vector and a microorganism for preparing human milk oligosaccharides. First, the present application obtains a BKHT protein with α-1,2-fucosyltransferase function by screening, which can specifically catalyze the synthesis of 2'-fucosyllactose; second, the above-mentioned BKHT protein is codon-optimized in the present application to obtain its coding gene sequence as shown in SEQ ID NO.2, and then a BKHT expression vector and a microorganism containing the BKHT coding gene and the BKHT expression vector are constructed, providing an engineering bacterium with good adaptability, high yield and no by-product generation for the synthesis of human milk oligosaccharides; third, the present application provides a method for preparing human milk oligosaccharides using the above-mentioned nucleic acid molecules, expression vectors and microorganisms, especially a method for preparing 2'-fucosyllactose.

[0006] In one aspect, the present application provides a nucleic acid molecule encoding a BKHT protein, wherein the nucleic acid molecule comprises a sequence as shown in SEQ ID NO.2 or a nucleotide sequence having at least 98% sequence identity with SEQ ID NO.2.

[0007] Preferably, the nucleic acid molecule comprises a nucleotide sequence having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity to SEQ ID NO.2.

[0008] More preferably, the nucleotide sequence of the nucleic acid molecule is as shown in SEQ ID NO.2.

[0009] Preferably, the amino acid sequence of the BKHT protein comprises the sequence shown in SEQ ID NO.1 or an amino acid sequence having at least 98% sequence identity with SEQ ID NO.1.

[0010] More preferably, the amino acid sequence of the BKHT protein is as shown in SEQ ID NO.1.

[0011] On the other hand, the present application also provides an expression vector containing the above nucleic acid molecule.

[0012] Preferably, the expression vector is a pET expression vector and / or a pRSF expression vector.

[0013] In a preferred embodiment, the pET expression vector is pET-AB-BKHT, and the construction method of pET-AB-BKHT is: using plasmid pET-ABW as a template and BKHT (sequence such as SEQ ID NO.2) as the target fragment to replace the wbgL gene in pET-ABW, and finally obtaining the expression vector pET-AB-BKHT.

[0014] Plasmid pET-ABW can be found in the Chinese patent document with publication number CN114874964A, which describes a construction method and application of a recombinant Escherichia coli with high production of 2'-fucosyllactose.

[0015] On the other hand, the present application also provides a microorganism, which contains the above-mentioned nucleic acid molecule and / or the above-mentioned expression vector.

[0016] Preferably, the microorganism contains the above-mentioned nucleic acid molecule and the above-mentioned expression vector.

[0017] In a preferred embodiment, the microorganism is BYBB, and the strain BYBB is obtained by co-transforming plasmids pRSF-CBGW and pET-AB-BKHT into the BWLBC strain (in which the BKHT coding sequence has been integrated).

[0018] Plasmid pRSF-CBGW can be found in Chinese patent document publication number CN112342176A, genetically engineered bacteria producing 2'-fucosyllactose and applications thereof.

[0019] Furthermore, the microorganism is one or more of Corynebacterium glutamicum, Bacillus subtilis, and Escherichia coli; preferably, the microorganism is Escherichia coli.

[0020] Preferably, the strong promoter is PJ23119; more preferably, the nucleotide sequence of PJ23119 is shown in SEQ ID NO.7.

[0021] In a preferred embodiment, Escherichia coli BL21 (DE3) is transformed to obtain strain BWLWC. In the present application, the nucleic acid molecule encoding the BKHT protein (SEQ ID NO.2) replaces the wbgL gene controlled by a strong promoter on the genome of the host strain BWLWC, thereby obtaining strain BWLBC. The nucleic acid molecule integrates the sgRNA target sequence as shown in SEQ ID NO.8.

[0022] The specific method for obtaining Escherichia coli BWLWC can be found in the Chinese patent document with publication number CN114874964A, which describes a construction method and application of a recombinant Escherichia coli with high production of 2'-fucosyllactose.

[0023] Those skilled in the art will appreciate that the above-mentioned transformation can be carried out using known gene editing methods, such as the CRISPR-Cpf1 gene editing system, the CRISPR-Cas9 gene editing system, RNA interference (RNAi)-mediated gene knockout, etc.

[0024] In a preferred embodiment, gene editing is performed using the CRISPR-Cpf1 gene editing system.

[0025] On the other hand, the present application also provides a whole-cell catalyst, which includes the above-mentioned microorganism.

[0026] On the other hand, the present application also provides the use of the above-mentioned nucleic acid molecules, or the above-mentioned expression vectors, or the above-mentioned microorganisms, or the above-mentioned whole-cell catalysts in the preparation of human milk oligosaccharides; preferably, the human milk oligosaccharides are 2'-fucosyllactose and / or 3'-fucosyllactose; more preferably, the human milk oligosaccharides are 2'-fucosyllactose.

[0027] On the other hand, the present application also provides a method for producing human milk oligosaccharides, which comprises using the above-mentioned nucleic acid molecules, or the above-mentioned expression vectors, or the above-mentioned microorganisms, or the above-mentioned whole-cell catalysts to produce human milk oligosaccharides; preferably, the human milk oligosaccharides are 2'-fucosyllactose and / or 3'-fucosyllactose; more preferably, the human milk oligosaccharides are 2'-fucosyllactose.

[0028] Preferably, the method for producing human milk oligosaccharides is specifically: using lactose as a substrate and glycerol as a carbon source, and utilizing the microorganism to ferment and prepare 2'-fucosyllactose.

[0029] More preferably, lactose and / or glycerol are added during the production process; more preferably, the concentration of lactose is 3-15 g / L; more preferably, the concentration of glycerol is 3-15 g / L.

[0030] More preferably, the concentration of lactose is 3 g / L, 4 g / L, 5 g / L, 6 g / L, 7 g / L, 8 g / L, 9 g / L, 10 g / L, 11 g / L, 12 g / L, 13 g / L, 14 g / L or 15 g / L.

[0031] More preferably, the concentration of lactose is 8 g / L.

[0032] More preferably, the concentration of the glycerol is 3 g / L, 4 g / L, 5 g / L, 6 g / L, 7 g / L, 8 g / L, 9 g / L, 10 g / L, 11 g / L, 12 g / L, 13 g / L, 14 g / L or 15 g / L.

[0033] In a preferred embodiment, a method for producing human milk oligosaccharides comprises the following steps: culturing the microorganism in LB medium at 37°C and 200 rpm for 8-12 hours to obtain a seed solution, transferring the seed solution to an initial fermentation medium at an inoculum amount of 2%, and growing the seed solution to an OD of 0. 600=0.6-0.8, add IPTG with a final concentration of 0.1 mM, and add 8 g / L lactose at the same time, and continue inducing culture at 25°C and 200 rpm for 72 h.

[0034] The yield of 2′-fucosyllactose in the method described in the present application can reach 94.68 g / L, and the lactose conversion rate can reach 0.98 mol 2′-FL / mol lactose, which is close to the theoretical conversion value, and there is no by-product difucosylatetraose.

[0035] On the other hand, the present application also provides a human milk oligosaccharide prepared by the above method; preferably, the human milk oligosaccharide is 2'-fucosyllactose and / or 3'-fucosyllactose; more preferably, the human milk oligosaccharide is 2'-fucosyllactose.

[0036] On the other hand, the present application also provides a composition, comprising the above-mentioned human milk oligosaccharide; preferably, the human milk oligosaccharide is 2'-fucosyllactose and / or 3-fucosyllactose; more preferably, the human milk oligosaccharide is 2'-fucosyllactose.

[0037] On the other hand, the present application also provides the use of the above-mentioned human milk oligosaccharides or the above-mentioned composition in the preparation of medicines, foods or cosmetics containing human milk oligosaccharides; preferably, the human milk oligosaccharides are 2'-fucosyllactose and / or 3-fucosyllactose; more preferably, the human milk oligosaccharides are 2'-fucosyllactose.

[0038] The present invention has the following beneficial effects:

[0039] 1. The α-1,2-fucosyltransferase BKHT obtained by screening in this application has excellent catalytic activity and strict substrate specificity, providing a new engineered enzyme for the preparation of human milk oligosaccharides;

[0040] 2. In the present application, the codon of BKHT protein was optimized to obtain its coding gene sequence as shown in SEQ ID NO.2, and then a BKHT expression vector and a microorganism containing the BKHT coding gene and the BKHT expression vector were constructed, providing an engineering bacterium with good adaptability, high yield and no by-product generation for the synthesis of human milk oligosaccharides;

[0041] 3. The new engineered bacteria provided in the present application are used to prepare 2'-fucosyllactose, the yield of 2'-fucosyllactose reaches 94.68 g / L, and the lactose conversion rate reaches 0.98 mol 2'-FL / mol lactose, especially the production of difucosyllactose without by-product, which significantly reduces the cost of downstream separation and purification and has good industrial prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:

[0043] Figure 1 The principles of engineering bacteria transformation and the synthetic route of 2'-FL;

[0044] Figure 2 It is a sequence alignment diagram of a new enzyme BKHT encoding a-1,2-glycosyltransferase specifically from Helicobacter sp.13S00401-1 and other enzymes encoding a-1,2-glycosyltransferases from Escherichia coli O126, H.pylori UA802 and B.fragilis NCTC9343;

[0045] Figure 3 HPAEC-PAD result diagram (A) and production capacity comparison diagram (B) of the fermentation product of 2'-fucosyllactose synthesized by the engineered bacteria;

[0046] Figure 4 The results of 2'-fucosyllactose HPAEC-PAD under different lactose concentrations (A) and the comparison of 2'-fucosyllactose production capacity (B);

[0047] Figure 5 This is a diagram showing the fermentation results of the engineered bacteria in a 5L fermenter to scale up the production of 2'-fucosyllactose. DETAILED DESCRIPTION

[0048] In order to more clearly explain the overall concept of the present application, the following is described in detail in conjunction with the accompanying drawings of the specification by way of embodiment. In the following description, a large number of specific details are provided to provide a more thorough understanding of the present invention. However, it is obvious to those skilled in the art that the present invention can be implemented without one or more of these details. In other examples, in order to avoid confusion with the present invention, some technical features well known in the art are not described.

[0049] If no specific conditions are specified in the examples, the experiments were carried out according to conventional conditions or conditions recommended by the manufacturer.

[0050] Unless otherwise specified, in the following embodiments, the reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0051] The plasmids, endonucleases, PCR enzymes, column-based DNA extraction kits, and DNA gel recovery kits used in the following examples are commercial products, and the specific operations are performed in accordance with the kit instructions.

[0052] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the field of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields, and can be specifically carried out according to Molecular Cloning: A Laboratory Manual (Fourth Edition).

[0053] The initial seed liquid culture medium used LB liquid culture medium, and the specific composition of the initial seed liquid culture medium was 10 g / L peptone, 5 g / L yeast extract, and 10 g / L sodium chloride.

[0054] The initial fermentation medium (i.e., glycerol quantitative medium) is used for glycerol quantification in the production of 2'-fucosyllactose. The specific composition of the initial fermentation medium is: 20 g / L glycerol, 13.5 g / L potassium dihydrogen phosphate, 4.0 g / L diammonium hydrogen phosphate, 1.7 g / L citric acid, 1.4 g / L magnesium sulfate heptahydrate, 4.5 mg / L thiamine and 10 ml / L trace elements (trace element mother solution: 10 g / L ferrous sulfate heptahydrate, 2.2 g / L zinc sulfate heptahydrate, 1.0 g / L copper sulfate pentahydrate, 0.38 g / L manganese sulfate monohydrate, 0.02 g / L sodium borate decahydrate, 0.1 g / L ammonium molybdate, 2.0 g / L anhydrous calcium chloride), and the pH of the initial fermentation medium is 6.8.

[0055] The glycerol supplementation system is: 600g / L glycerol, 20g / L magnesium sulfate heptahydrate, and 0.2g / L thiamine.

[0056] Lactose supplement system: 200g / L lactose.

[0057] HPLC configuration and detection parameters:

[0058] Chromatographic column: Carbohydrate Analysis (Rezex ROA-organic acid H+(8%)); detector: differential detector; mobile phase: 0.5mmol / L, H2SO4; flow rate: 0.6mL / min; column temperature: 60℃; injection volume: 10μL.

[0059] HPAEC-PAD configuration and detection parameters:

[0060] Chromatographic column: Dionex CarboPac PA10 column (4mm×250mm); Detector: Pulse current detector; Mobile phase: Gradient elution using three eluents, including A: ultrapure water, B: 1M sodium acetate and C: 250mM NaOH. Use the following gradient elution, elution program: 0-15min, 40% A: 0% B: 60% C to 31% A: 9% B: 60% C; 15-15.1min, 31% A: 9% B: 60% C to 40% A: 0% B: 60% C; 15.1-25min, 40% A: 0% B: 60% C; all V / V. The flow rate was set to 1.0mL / min.

[0061] In the present application, the above-mentioned E. coli BWLWC is used as a template, and the CRISPR-Cpf1 gene editing system is used to target the nucleic acid molecule encoding the BKHT protein to replace the wbgL gene controlled by the strong promoter on the genome of E. coli BWLWC to obtain the strain BWLBC. The specific transformation principle is as follows: Figure 1 shown.

[0062] Among them, the construction of plasmid pET-ABW includes:

[0063] The rcsA and rcsB genes were amplified from the chromosome of Escherichia coli K-12MG1655 using rcsA-F / R and rcsB-F / R, respectively, and the vector fragment was amplified from pET-W (the wbgl gene fragment was connected to the pETDuet-1 vector) using rcsAB-VF / R, and the DNA fragment was recovered by gel. The rcsA and rcsB gene fragments obtained by the above amplification and the vector fragment were connected through the Gibson kit (NEB Reagent Company, USA) to obtain the plasmid pET-ABW, and the expression of the pathway enzyme gene was regulated by the rcsA and rcsB positive transcription regulatory factors.

[0064] The construction method of pET-AB-BKHT in the present application is: using plasmid pET-ABW as a template and BKHT (sequence such as SEQ ID NO.2) as a target fragment to replace the wbgL gene in pET-ABW.

[0065] The plasmid pET-ABW and the host (Escherichia coli) BWLWC can be found in the Chinese patent document with publication number CN114874964A, which describes a construction method and application of a recombinant Escherichia coli with high production of 2'-fucosyllactose.

[0066] The plasmid pRSF-CBGW can be found in the Chinese patent document with publication number CN112342176A, a genetically engineered bacterium producing 2'-fucosyllactose and its application.

[0067] Example 1 Screening of an enzyme with fucosyltransferase function and construction of its expression vector

[0068] In this example, based on the NCBI database (https: / / www.ncbi.nlm.nih.gov / ), the classic fucT2 and wbgL in the glycosyltransferase family were used as templates, and the BLAST module on the NCBI website was screened one by one, and the key conserved sites and similarities were compared to obtain a new enzyme from Helicobacter pylori sp.13S00401-1, named BKHT (GenBank: PAF50342.1), and its amino acid sequence is shown in SEQ ID NO.1.

[0069] The amino acid sequence alignment of the enzyme BKHT from Helicobacter sp. 13S00401-1 and other enzymes wbgL from Escherichia coli O126, fucT2 from H. pylori UA802, and wcfB from B. fragilis NCTC 9343 is shown below: Figure 2 As shown. Figure 2 The results showed that the amino acid sequence of BKHT was only 31.05% similar to the amino acid sequence of the currently published ɑ-1,2-fucosyltransferase fucT2 from Helicobacter pylori (GenBank: AAC99764.1); the amino acid sequence of BKHT was only 30.58% similar to the amino acid sequence of the currently published ɑ-1,2-fucosyltransferase wbgL from Escherichia coli O126 (GenBank: ADN43847.1); and the amino acid sequence of Bacteroides fragilis (GenBank: CAH06753.1) was only 32.85%. Therefore, BKHT is a new ɑ-1,2-fucosyltransferase.

[0070] In this example, the pET-AB-BKHT expression vector was constructed using the plasmid pET-ABW as a template and the above-mentioned BKHT as the target fragment. The specific sequence of the target fragment after codon optimization is shown in SEQ ID NO. 2. At the same time, the pET-AB-BKHT-1 expression vector was also constructed, in which the target fragment was not codon optimized, and its specific sequence is shown in SEQ ID NO. 3 (GenBank: MLAR01000006.1).

[0071] In addition, in this example, α-1,2-fucosyltransferases from three other sources were annotated based on the NCBI database, and were named wbgL, fucT2, and wcfB, respectively. The specific sequences after codon optimization are shown in SEQ ID NO. 4, SEQ ID NO. 5, and SEQ ID NO. 6. The pET-ABW plasmid was used as a template (i.e., pET-AB-wbgL) to construct pET-AB-fucT2 and pET-AB-wcfB expression vectors.

[0072] In this example, plasmid pRSF-CBGW and the above-constructed pET expression vector (pET expression vector represents pET-AB-wbgL, pET-AB-fucT2, pET-AB-wcfB, pET-AB-BKHT or pET-AB-BKHT-1) were co-transformed into Escherichia coli BL21 (DE3) △lacZ△wcaJ to obtain strains BY01, BY02, BY03, BY04 and BY05 for shake flask fermentation verification.

[0073] The specific method of shake flask fermentation verification is as follows: strain BY01, BY02, BY03, BY04 or BY05 was grown overnight on a resistance agar plate and then inoculated into 4 mL LB medium with the corresponding antibiotic as the initial seed solution, and cultured at 37°C, 200 rpm for 8-12 h; 2 mL of the initial seed solution was inoculated into a glycerol quantitative medium (100 mL volume) with the corresponding antibiotic, and continued to grow under the same culture parameters until OD 600 =0.6-0.8, then add IPTG with a final concentration of 0.1mM, and add 8g / L lactose at the same time, and continue to induce culture for 72h at 25°C and 200rpm. Take 1mL of fermentation broth, centrifuge at 10000rpm for 10min, take the supernatant, and use it for HPAEC-PAD determination. The shake flask fermentation verification results are shown in Table 1.

[0074] Plasmid pET-ABW and its preparation method can be found in Chinese patent document with publication number CN114874964A, which records a construction method and application of a recombinant Escherichia coli with high production of 2'-fucosyllactose; plasmid pRSF-CBGW can be found in Chinese patent document with publication number CN112342176A, which records a genetically engineered bacterium producing 2'-fucosyllactose and its application.

[0075] Table 1. Productivity information of BL21(DE3)△lacZ△wcaJ engineered strain for 2'-fucosyllactose production

[0076]

[0077]

[0078] The results are shown in Table 1 and Figure 3 As shown, in the culture of engineered E. coli expressing WbgL, FucT2, WcfB, BKHT and BKHT-1, 4.15, 3.16, 3.67, 7.90 and 1.77 g / L of 2'-fucosyllactose (2'-FL) were produced extracellularly. In terms of producing 2'-FL, the strain BY04 expressing BKHT had a higher advantage than BY01, BY02 and BY03, with an increase of more than 1.90 times; and the strain BY04 expressing codon-optimized BKHT had a higher advantage than BY05 without codon optimization, with an increase of more than 4.46 times; indicating that codon optimization for heterologous protein expression and selection of synonymous codons corresponding to high-abundance tRNA are beneficial to improving the expression of the protein, thereby giving it a higher production potential. Similarly, strain BY04 had the highest lactose conversion rate of 0.95 mol 2'-FL / mol lactose, which was 1.20, 1.27, and 1.17 times higher than those of strains BY01, BY02, and BY03; in addition, strain BY01 (expressing wbgL) produced 0.24 g / L of difucosylatetraose and 0.06 g / L of 3-fucosyllactose, while BY02 (expressing fucT2) produced 0.65 g / L of difucosylatetraose. No production of difucosylatetraose and 3-fucosyllactose was observed in strains BY03 and BY04 expressing WcfB and BKHT, respectively. This indicates that the high activity and enzyme specificity of α-1,2-fucosyltransferase are one of the key limiting factors for the large-scale production of 2'-FL. The enzyme BKHT newly screened from Helicobacter sp. 13S00401-1 in Example 1 has high 2'-FL production activity as an α-1,2-fucosyltransferase, and does not produce by-products, and has strong production potential.

[0079] Example 2 Construction and verification of recombinant strains for 2′-fucosyllactose production

[0080] In this example, the host BWLWC was used as a template, and the CRISPR-Cpf1 gene editing system was used to integrate the target new enzyme BKHT, targeting wbgL in the genome of E. coli BWLWC, and the constitutive promoter PJ23119 (nucleotide sequence as shown in SEQ ID NO.7) was used to replace the original promoter to control the expression of BKHT. The specific operation is as follows:

[0081] The E. coli BWLWC genome was used as the amplification template for the target fragments UP and Down, and the upstream sequence fragment of the recA site was amplified using recA-UP-F / recA-UP-R primers. Similarly, the downstream sequence fragment was amplified using recA-Down-F / recA-Down-R; the PJ23119-BKHT-T7 terminator fragment was placed between the upstream and downstream fragments, and formed homology arms with the upstream and downstream fragments during amplification. The three-fragment amplification products were purified by gel recovery, and then connected by overlapping PCR amplification to obtain the target donor DNA template ZH-BKHT; the original pEcgRNA-N23 plasmid was used as a template to search for the crRNA target sequence N23 (nucleotide sequence as SEQ ID NO.8) to replace the original sequence for the localized cutting and recombination of Cpf1; the correctly sequenced pEcgRNA-wbgL-N23 (200ng) and ZH-BKHT (800ng) fragments were electrotransformed into the target strain with Cpf1 electrotransformation competence, and the electrotransformation instrument voltage was set to 2.5kv (2mm electrotransformation cup). After electrotransformation, 900μL LB pre-cooled on ice was added immediately, and after incubation at 37℃ for 1h, kanamycin (Kan) and spectinomycin (Spc) double-antibody plates were coated and cultured in a 37℃ oven overnight. After subsequent sequencing verification, the strain BWLBC with integrated BKHT can be obtained.

[0082] Among them, the nucleotide sequence of the target donor DNA template ZH-BKHT is: TCTGTGCGGTATT TCACACCGCATATGCTGGATCCTTGACAGCTAGCTCAGTCCTAGGTATAATGCTAGCGTGATCAGACCTTTGTTTAACTTTAAAGGAGGTGATAAAAATGAAAAACAAAGTGCAGATTAAAATGCAAGGCCGCCTGGGCAATCAGTTTTTTATTTATGCGTTTGCGAAAAGTTTACTGCACAAACTGCAGAGCAGCGATAACCTGGATATTAAAAAAACCAAAGTGATTCTGCTGTGCGATGAATATGAAAACCTGGCGAGCGCGGATATTTTTAAATATAACATTGATCTGAGCCTGTTTGATCTGAAATTTTATGGCAGCCGCATTAGCAGTAGCAACTTTTTTCTGCGCGCGACCCGCAAGGCGATTTATCTGAGCACCGGCACCGTGATTCGCATTGGCATTAAAGATACCGCGAAAAAGAAAAGCTTTTATATTCAGCTGCCGATTCTGACCGAAACCTATACCCAAGGCGAATTTGATGAAAACGTGATTAAAGATTGCCTGAACAAATGCCTGCTGGGTTATTTTCAGAGCGAACTGTATTTTGAAGATATTAAAGAAAGCCTGAAAAAAGATTTTGTGCTGAAAGCGCCGCTGAAAAGCAAAACGCAGAAAGCGCTGACCAAAATTCGCCAAGATAGCAAAGCGATCTTTGTGCATATTCGCCGCGGCGATTATCTGGCGCCGGCGAACATTACCCTGTATGCGAGCCTGGGCGCGAACTACTATAAAAGTGCGATTAAACTGGCGCTGGAAAAAATTCCGGATGCGAAATTTTATATTTTTAGCGATGATATTGCGTGGGTGAAAGAAGAAGGCAAAAGCCTGCTGGGCTTTGAAGGCCTGGAATGCGAATTTATGGATCTGCATGGCGAAAACGAAGGCTATCTGGATCTGGAACTGATGCGCGCGTGCAAAGGCGCGATTACCGCGAACAGCAGCTTTAGCTGGTGGGGCGCGTATCTGATTGAAGAACCGAAAGTGGTGATTGCGCCGTTTCCGTTTCATTTTATTCATAGCAACGTGGATCTGTTACTGGATAGCTGGATTGTGCTGGATTATAAGAGTGGCGATGTGCTGAAAAAAGAAGATTATCTGTATGAAACCCTGAAAACCAAAAACAAACAAGAAAGCAACAGCAAAAGCACGAGCAGCTATTTTCGCTTTCATAACAGCAGCGGCGGTGGCGGTGGCAACACCTTTCGCTATGGTCAGTAATTAACCTAGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG;

[0083]

[0084] Steps for removing pEcgRNA-wbgL-N23 and Cpf1 in the recombinant strain BWLBC: The bacteria successfully verified by sequencing were inoculated in a 4mL LB test tube (rhamnose and 2μL kanamycin were added at a final concentration of 10mM at the time of inoculation) and cultured at 37°C for 10-12h. After the end, streaks were made on the kanamycin (Kan) plate and cultured at 37°C; after a single colony grew on the plate, streaks were made on the plates (Kan plate and Kan+Spc plate) and cultured at 37°C. The bacteria that grew on the Kan plate but did not grow on the double-antibody were the successful removal of pEcgRNA-wbgL-N23; then the single colony was further inoculated into a liquid LB medium containing glucose (5g / L) and cultured at 37°C and 200rpm for 10-12h. Then, about 10μL of the bacterial solution was streaked on a plate containing 5g / L glucose + 10g / L sucrose and cultured at 37°C for 10-12h. Single colonies were randomly selected and streaked on plates without antibiotics and plates containing Kan. The bacteria that grew on the plates without antibiotics and did not grow on the Kan plates were the hosts from which the plasmid was finally successfully removed.

[0085] The plasmids pRSF-CBGW and pET-AB-BKHT involved in the above Example 1 were co-transformed into the above target engineering bacteria BWLBC to obtain the final recombinant bacteria BYBB.

[0086] The plasmid pRSF-CBGW can be seen in the Chinese patent document with publication number CN112342176A, which records the genetic engineering bacteria producing 2'-fucosyllactose and its application; the host BWLWC can be seen in the Chinese patent document with publication number CN114874964A, which records the construction method and application of a recombinant Escherichia coli with high production of 2'-fucosyllactose.

[0087] The recombinant strain BYBB was verified by shake flask fermentation. 5, 8, 10, and 15 g / L lactose were added during induction. The specific shake flask fermentation method was the same as in Example 1. The results are shown in Table 2.

[0088] Table 2. Productivity information of BYBB engineered strains for 2′-fucosyllactose production

[0089]

[0090] As shown in Table 2 and Figure 4 The results showed that the yield of 2'-fucosyllactose could reach 11.13 g / L, 8 g / L lactose was completely consumed, the lactose conversion rate reached 0.98 mol 2'-FL / mol lactose, and OD 600 It is 10.6.

[0091] When the added lactose concentration was lower than 10 g / L, the yield of the product 2'-FL increased with the increase of lactose concentration. When the added lactose concentration was 15 g / L, the yield of 2'-FL and the lactose conversion rate decreased slightly, which may be because the high lactose concentration was not conducive to the growth of the strain or the activity of α-1,2-fucosyltransferase. In general, the addition of 5 and 8 g / L lactose was exhausted at the end of fermentation, and the yield of 2'-FL and the lactose conversion rate almost reached the theoretical maximum. The yield of 2'-FL in lactose produced by the BYBB strain reached 0.98 mol 2'-FL / mol lactose, which is close to the theoretical conversion value.

[0092] Example 3 Fed-batch fermentation experiment

[0093] In order to further verify the scale-up production effect of the recombinant strain BYBB described in Example 2, a fed-batch fermentation experiment was carried out in this example.

[0094] The specific steps of the fed-batch fermentation experiment were as follows: the BYBB plate strain grown overnight was transferred to 4 mL LB liquid medium with the corresponding antibiotics as the primary initial seed liquid and cultured at 37 °C for about 12 h. The OD 600 At about 2.5, the first-level seed solution was then inoculated into the second-level glycerol quantitative culture medium (with corresponding antibiotics and thiamine for plasmid resistance screening and strain growth) at an initial inoculum volume of 2% (v / v), and cultured for about 10 h under the same temperature and speed conditions until OD 600 Between 1.8-2.2; inoculate the secondary seed liquid at an inoculation ratio of 10% (v / v) into a 5L fermentation tank containing 1.5L glycerol quantitative culture medium (glycerol is 30g / L), set the dissolved oxygen to 30%, the culture temperature to 37°C, the rotation speed associated with the dissolved oxygen, the stirring speed to 200-800rpm, the ventilation volume to 2-8vvm, and the pH to 6.75.

[0095] Culture OD 600 When the temperature reaches about 15-18 °C, add IPTG with a final concentration of 0.1 mM and lactose with a final concentration of 8 g / L, and change the culture temperature to 25 °C. The pH during the growth process is regulated with ammonia water to maintain the pH stability of the entire fermentation. During the fermentation, the consumption of lactose and glycerol is checked from time to time, and the concentration of lactose and glycerol is kept at 3-15 g / L as much as possible to improve the empirical high production capacity. After the fermentation is completed, take 1 mL of the fermentation broth and centrifuge it at 12000 rpm for 2-3 minutes at room temperature. After the supernatant is filtered with a water filter (0.22 μm), HPLC detection is performed, and qualitative and quantitative detection is performed according to the standard product information.

[0096] like Figure 5As shown in the figure, the bacterial biomass and 2′-FL accumulation showed a positive correlation in the early stage of fermentation. After about 30 hours of fermentation, the strain gradually entered the stable period, and the product accumulation rate began to slow down significantly. During the fermentation process, the feed was fed, and the final concentration of lactose and glycerol feed was controlled between 3-15g / L. The whole fermentation time was not less than 80h, and the final bacterial OD 600 It reached about 85, the yield of 2′-fucosyllactose reached 94.68 g / L, and the lactose conversion rate reached 0.98 mol 2′-FL / mol lactose.

[0097] The above is only an embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.

Claims

1. A nucleic acid molecule encoding a BKHT protein, characterized in that: The nucleic acid molecule is shown as SEQ ID NO.

2.

2. An expression vector containing the nucleic acid molecule of claim 1.

3. A microorganism, characterized in that The microorganism contains the nucleic acid molecule according to claim 1 and / or the expression vector according to claim 2, and the microorganism is Escherichia coli.

4. A whole cell catalyst, characterized in that The whole-cell catalyst comprises the microorganism according to claim 3.

5. Use of the nucleic acid molecule according to claim 1, or the expression vector according to claim 2, or the microorganism according to claim 3, or the whole-cell catalyst according to claim 4 in the preparation of 2'-fucosyllactose.

6. A method for producing 2'-fucosyllactose, characterized in that The method comprises producing 2'-fucosyllactose using the nucleic acid molecule of claim 1, or the expression vector of claim 2, or the microorganism of claim 3, or the whole cell catalyst of claim 4.